Skip to main content
Accolade, Inc. (ACCD)
NASDAQ: ACCD · IEX Real-Time Price · USD
7.63
+0.15 (2.01%)
May 20, 2024, 1:51 PM EDT - Market open

Accolade Revenue

In the fiscal year ending February 28, 2024, Accolade had annual revenue of $414.29M with 14.09% growth. Revenue in the quarter ending February 28, 2024 was $124.83M with 26.06% year-over-year growth.

Revenue (ttm)
$414.29M
Revenue Growth
+14.09%
P/S Ratio
1.44
Revenue / Employee
$172,622
Employees
2,400
Market Cap
597.47M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Feb 28, 2024414.29M51.15M14.09%
Feb 28, 2023363.14M53.12M17.13%
Feb 28, 2022310.02M139.66M81.98%
Feb 28, 2021170.36M37.85M28.57%
Feb 28, 2020132.51M37.70M39.76%
Feb 28, 201994.81M17.98M23.41%
Feb 28, 201876.83M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
PetIQ 1.12B
GeneDx Holdings 221.85M
Harrow Health 138.68M
Avid Bioservices 136.74M
Calliditas Therapeutics AB (publ) 119.73M
Taysha Gene Therapies 14.16M
Allogene Therapeutics 65.00K
Revenue Rankings

ACCD News

More News